Compare ENS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENS | ERAS |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | 9200 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.5B |
| IPO Year | 2004 | 2021 |
| Metric | ENS | ERAS |
|---|---|---|
| Price | $212.79 | $10.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $193.00 | $14.25 |
| AVG Volume (30 Days) | 225.4K | ★ 8.7M |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.51% | N/A |
| EPS Growth | ★ 38.31 | 36.23 |
| EPS | ★ 5.65 | N/A |
| Revenue | ★ $216,125,000.00 | N/A |
| Revenue This Year | $4.49 | N/A |
| Revenue Next Year | $3.41 | N/A |
| P/E Ratio | $36.32 | ★ N/A |
| Revenue Growth | ★ 15.85 | N/A |
| 52 Week Low | $76.60 | $1.06 |
| 52 Week High | $211.79 | $24.28 |
| Indicator | ENS | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 72.29 | 32.94 |
| Support Level | $154.95 | $1.98 |
| Resistance Level | N/A | $17.17 |
| Average True Range (ATR) | 5.16 | 2.12 |
| MACD | 0.65 | -1.33 |
| Stochastic Oscillator | 95.82 | 9.95 |
EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, and Specialty.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.